Fin Cascade

Prices as of 20 Nov 2026 close · Not investment advice

Updated 21 Nov, 21:20 IST

Evonile Pharma Limited

NSE: EVONILE · Pharmaceuticals

Share price ₹1,367.60

down 1.82% · close of 20 Nov 2026

Business scoreHow strong the business is, in one number.Changed 20 Nov 2026How it was built →

Your ratios

Market cap

₹4,784 Cr

P/E ratio

74.4

EPS TTM to Sep 2026

P/B ratio

6.2

ROCE

16.3%

ROE

11.6%

Dividend yield

0.0%

as of 19 Nov 2026

Profit checks10/10 clear

1 · Overview

Overview

Price, valuation, sales and profit over the range you pick. Prices as of the last close; results as filed.

Up candleDown candle
Volume, average a day
Latest
16 Nov – 20 Nov 2026
Open₹1,519.90
High₹1,519.90
Low₹1,352.00
Close₹1,367.60
Change on the week−10.05%
50 DMA₹1,606.05
200 DMA₹1,184.52
Avg volume a day28.6k
Return · 1Yr
+95.55%
₹699.36 → ₹1,367.60
From the 1Yr high
−33.07%
High ₹2,043.31 · 10 Sep 2026
From the 1Yr low
+114.04%
Low ₹638.95 · 30 Jan 2026
From the 200 DMA
+15.46%
200 DMA ₹1,184.52

One candle a week · body: open to close, green when it closed higher · line: high to low

At a glance · 1Yr

Every small chart follows the range above. Point at it to read a value; click it to open it.
P/E
74.4
1Yr range 21.3 – 86.5
Nov 2025 – Nov 2026
Revenue (sales)
₹56.0 Cr
Sep 2026 · −37.78% on a year ago
Sep 2025 – Sep 2026 · 5 quarters
Operating margin
−57.0%
average 10.4% · low −57.0% · high 34.0%
Sep 2025 – Sep 2026 · 5 quarters
Net profit
−₹78.0 Cr
Sep 2026 · −425.00% on a year ago
Sep 2025 – Sep 2026 · 5 quarters
EPS (yearly)
₹31.80
FY26 · −7.67% on FY25
FY23 – FY26 · 4 years
ROCE (yearly)
16%
FY26 · average 16% over 1 year
FY26 – FY26 · 1 year (all we have)
Free cash flow (yearly)
₹46.7 Cr
FY26 · 50% of net profit
FY15 – FY26 · 3 years (all we have)
Promoter holding
70.68%
FII 1.2% · DII 1.5% · no change in a year
Sep 2025 – Sep 2026 · 5 quarters

2 · Results

Latest result · Q2 FY27

What the last results showed. Whether management kept its word is in Pro.

Net profit -₹78.0 Cr, down 425.0% on Sep 2025

Announced 3 Nov 2026 · Standalone · Unaudited

Sales₹56.0 Crdown 37.8% on Sep 2025
Operating profit-₹32.0 Crdown 233.3% on Sep 2025
Operating margin-57.0%down 83.0 pts from 26.0%
Net profit-₹78.0 Crdown 425.0% on Sep 2025
Net margin-139.3%down 166.0 pts from 26.7%
EPS₹-26.46down 420.0% on Sep 2025
Sales, last 8 quarters ₹ crore

Earnings call transcript · 4 Nov 2026

Show
Standalone
Sales, operating profit and net profit, ₹ crore: 12 years to Mar 2026, then the last 12 months (the fainter bars).
TTMLast 12 months to Sep 2026
Sales₹337.00 Cr
Operating profit₹46.00 Cr13.6% of sales
Net loss−₹5.00 Cr-1.5% of sales
P/E74.4On 20 Nov 2026
Inside each sales bar: operating profit, and inside that, net profit.OPM: operating profit as % of sales. NPM: net profit as % of sales. Dashed line: the median of the P/E values shown (30.6)P/E on the last trading day of each period: that day's share price ÷ the 12-month earnings per share published by then. Blank where none is on record.

12 years, Mar 2015 to Mar 2026, and the last 12 months · key lines

Yearly profit and loss, 12 years, Mar 2015 to Mar 2026, and the last 12 months
LineMar 2015FY15Mar 2016FY16Mar 2017FY17Mar 2018FY18Mar 2019FY19Mar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26TTMto Sep 2026
Sales₹ crore870.00690.00change on a year before -21%656.00change on a year before -5%564.00change on a year before -14%491.00change on a year before -13%438.00change on a year before -11%381.00change on a year before -13%400.00change on a year before +5%379.00change on a year before -5%335.07change on a year before -12%356.27change on a year before +6%354.33337.00change on a year before -5%
Operating profit₹ crore-43425change on a year before -26%-6change on a year before -124%1212change on a year before 0%27change on a year before +125%27change on a year before 0%65change on a year before +141%65change on a year before 0%91change on a year before +40%9446change on a year before -54%
Operating margin% of sales-0.40%5.00%3.80%-1.10%2.50%2.80%7.00%7.00%17.00%19.00%26.00%27.00%13.65%
Other income₹ crore10120771172783633-1758624239-33
Net profit₹ crore79.00198.00change on a year before +151%57.00change on a year before -71%78.00change on a year before +37%52.00change on a year before -33%10.00change on a year before -81%21.00change on a year before +110%-4.00change on a year before -119%103.0085.19change on a year before -17%100.90change on a year before +18%93.18-5.00change on a year before -105%
EPS₹ per share20.8252.18change on a year before +151%17.13change on a year before -67%26.74change on a year before +56%17.67change on a year before -34%3.44change on a year before -81%7.13change on a year before +107%-1.27change on a year before -118%35.2829.08change on a year before -18%34.44change on a year before +18%31.80-1.36change on a year before -104%
Dividend paid out% of net profit40.00%16.00%49.00%32.00%48.00%245.00%118.00%-663.00%113.00%72.00%61.00%66.00%

Small figure: change on the year before (TTM: on the 12 months to Sep 2025). TTM = the four quarters to Sep 2026. Lines that are 0 or blank in every column are not shown.

Sales and profit: growth a year, compounded, to Mar 2026; TTM is the last 12 months. Share price: to the latest close. A span can cross a demerger or an acquisition.

Sales

a year, compounded

10 years
-6%
5 years
-1%
3 years
-2%
TTM
-5%

Profit

a year, compounded

10 years
-7%
5 years
35%
3 years
-3%
TTM
-39%

Share price

a year, compounded

10 years
10%
5 years
16%
3 years
34%
1 year
104%

Return on equity

average over the span

10 years
8%
5 years
11%
3 years
12%
Last year
12%

3 · Quality & value

Answers

The questions investors ask most, each answered first in one line, then shown. From the company's own numbers.

How fast it has been growing

Sales fell 5.1% over the past year.

Meanwhile what it keeps of every 100 rupees of sales slipped from 13.7% to 6.5% over the last four years.

Whether it grew faster than its sector

It grew -2.2% a year against a sector median of 9.9% — 12.2 percentage points slower.

EVONILE−2.2% a year
Sector median9.9% a year

Room to re-rate, or risk of de-rating

At 74.4× earnings it costs 3.2× the market, which pays 23.0× across 2,280 companies we can price.

EVONILE now74.4×
Its industry (5)81.1×
All 2,280 priced23.0×
Its own 5-year median31.2×

Its own industry sits at 81.1×, across 5 companies. It is against its own five-year median of 31.2×, the 99th percentile of its own range.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 58 of 132 on returns, 123 of 129 on growth, 37 of 132 on margin.

Returns on capital58 of 132
Margin37 of 132
Growth123 of 129

A longer bar is a better rank.

What makes it hard to beat — and is that still true?

A narrow advantage: it earns 16.3% on capital, ahead of 56% of companies filed under the same label.

Return on capital16.3%
Ahead of56% of peers

Whether its growth pays for itself

Yes — Over the last five years it made ₹319 crore of cash from the business, spent ₹1 crore on plant and equipment, and returned ₹315 crore to lenders and shareholders.

But only about 17 of every 100 rupees of profit it reported over 12 years arrived as cash — the rest is tied up.

Peers here are the 132 companies the exchange files under the same label (Pharmaceuticals). That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Business score & profit checks

How strong the business is, and whether its profit is real cash. Facts only, not advice.

Business score

38 out of 100

How strong the business is, in one number. Last changed 20 Nov 2026.

How the business score works

Profit checks: is the profit real cash?

10 of 10 checks clear

Simple checks on the accounts.

How the profit check works

PROHow the score was builtEach part of the score, with the numbers behind it
PROWhich checks were flaggedEvery check, the watch list and the filings behind them
PROFrom the filingsLoan defaults, and money lent or guaranteed to the promoters’ side
PROThe case for and againstA weighted list of what looks good and what looks weak

Key numbers & peers

Grouped by topic. Each number says what period it is for.

Price

Market cap
₹4,784 Cr
Prev close
₹1,367.60
52w High
₹2,178
52w Low
₹631
Beta
0.3
Price CAGR 1y
104.0%
Price CAGR 3y
34.0%
Price CAGR 5y
16.0%
Price CAGR 10y
10.0%

Valuation

P/E ratioEPS TTM to Sep 2026
74.4
Industry P/E
34.7
P/B ratio
6.2
EV / EBITDA
114.7
Enterprise value
₹5,277 Cr
PEG ratio
—
Dividend yield
0.0%

Returns

ROCE
16.3%
ROCE 5y average
14.0%
ROE
11.6%
ROE 3y average
12.0%
ROE last year
12.0%
Return on assets
9.5%

Sales, profit & margins

Annual revenue
₹354 Cr
Annual profit
₹93.0 Cr
EPS
₹31.8
Operating margin
26.6%
Net profit margin
26.3%
EBITDA margin
26.6%
Sales latest quarterSep 2026 quarter
₹56.0 Cr
Profit latest quarterSep 2026 quarter
-₹78.0 Cr
OPM latest quarterSep 2026 quarter
-57.0%

Growth a year

Sales growth 3y
-2.2%
Sales growth 5y
-1.5%
Sales growth TTM
-5.0%
Profit growth 3y
-3.3%
Profit growth 5y
34.7%
Profit growth TTM
-39.5%
YoY quarterly sales growthSep 2026 vs Sep 2025
-37.8%
YoY quarterly profit growthSep 2026 vs Sep 2025
-425.0%

Balance sheet

Book Value
₹220
Face Value
₹5.0
Borrowings
₹3.00 Cr
Total debt
₹796 Cr
Total cash
₹253 Cr
Net debthalf-year 30 Sep · excl. leases
₹493 Cr
Debt / Equity
1.0
Interest coverage
103.9
Reserves / Equity
67.1

Cash & payout

Operating cash flow
₹47.0 Cr
Free cash flow
₹46.4 Cr
FCF yield
0.9%
Net cash flow
₹0.00 Cr
Dividend payout
66.0%

Holdings

Promoter holding
70.7%
FII holding
1.2%
DII holding
1.5%
Public holding
26.6%

Enterprise value, step by step

What buying the whole company would cost: its market value, less the cash it holds over its debt. Net debt from the balance sheet of 30 Sep 2026.

  1. Market cap₹4,784 Cr
  2. +Net debt₹493 Cr
  3. =Enterprise value₹5,277 Cr

Peers

Peers
CompanyPrice ₹P/EMkt cap ₹ CrDiv yieldProfit qtr ₹ CrProfit changeSales qtr ₹ CrSales changeROCE
Sun Pharmaceutical1,884.9036.84,52,2440.86%1,995-36.16%16,199+11.88%20.60%
Divi's Laboratories11,180.5086.72,96,2830.27%1,127+63.57%3,676+35.40%21.97%
Torrent Pharmaceuticals4,689.5081.11,78,3700.82%534-9.64%4,979+50.79%19.56%
Laurus Labs Limited2,294.6092.51,23,9770.09%436+124.84%2,206+33.44%17.97%
Zydus Lifesciences1,200.0026.21,19,7600.08%928-25.13%7,910+29.17%22.69%
Dr Reddy's Laboratories1,390.2041.51,16,0820.58%913-31.70%8,698-1.48%13.75%
Cipla1,415.0036.81,14,3110.93%852-37.07%7,404-2.44%16.66%
Evonile Pharma Limited1,367.6074.44,7840.00%-78.0-425.00%56.0-37.78%16.27%
Medianof the whole group of 129, 20 Nov 202634.90.09%+33.42%+19.60%15.01%

Median: the middle value of the whole peer group of 129 companies. Price and rupee sizes are left blank there, as a middle value of those says little.

Competes with 7 listed companies

Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Sun Pharmaceutical, Torrent Pharmaceuticals, Zydus Lifesciences

4 · Balance sheet & cash

Balance sheet

What the company owns and what it owes, at each year end and at the filed half-years. ₹ crore.

Standalone

At Sep 2026: ₹2,278 cr of assets, and who funds them

Shareholders’ own money funds 34% of it; borrowings 35%.

What it owns

  • Fixed assets ₹1,310 cr 58%
  • Investments ₹50.0 cr 2%
  • Owed by customers ₹22.4 cr 1%
  • Cash ₹253 cr 11%
  • Everything else ₹643 cr 28%

Who funds it

  • Shareholders’ money ₹772 cr 34%
  • Borrowings ₹796 cr 35%
  • Owed to suppliers ₹194 cr 9%
  • Everything else ₹516 cr 23%

Each year end, then the filed half-years. Newest year end and newest half-year shaded.

Balance sheet
Line, ₹ croreMar 2015FY15Mar 2016FY16Mar 2017FY17Mar 2018FY18Mar 2019FY19Mar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26Sep 20266 months
Equity capital16161412121212121212121212.34
Reserves9861,178906721747708699679763732773805759.38
Borrowings0000068622422753796.01
Other liabilities244239230377223289229242186173158157—
of which owed to suppliers————————————193.66
Total funding1,2461,4331,1501,1119821,0781,0029589839259489782,277.66
Fixed assets866515766424197531,310.07
Investments00000000000050
of which current————————————50
Other assetsreceivables, cash, rest1,2381,4261,1441,1069671,001938934964918943975917.59
of which owed by customers————————————22.35
of which stock————————————164.19
of which cash————————————252.56
Total assets1,2461,4331,1501,1119821,0781,0029589839259489782,277.66

Half-year filings list fewer lines: there, Other assets is the total less the three lines above it, and Other liabilities is not filed as one line. Some half-year filings leave out leases, so Borrowings and Fixed assets can be lower than at the year end.

Cash flows

Real money coming in and going out — from the business, from investments and from loans. ₹ crore.

Standalone

Pick a period to see where its cash went.

Where the cash went, year to Mar 2026, ₹ crore

In words

  • The business brought in ₹46.7 cr, 50% of its operating profit before tax.
  • Investing brought in ₹18.0 cr, more than it put in.
  • It paid out ₹64.0 cr to shareholders and lenders, 137% of what the business brought in.
  • Cash in hand rose by ₹0.00 cr. Free cash flow: ₹46.7 cr.
Cash flow
Line, ₹ croreMar 2015FY15Mar 2016FY16Mar 2017FY17Mar 2018FY18Mar 2019FY19Mar 2020FY20Mar 2021FY21Mar 2022FY22Mar 2023FY23Mar 2024FY24Mar 2025FY25Mar 2026FY26Sep 20266 months
From the business-60.0057.00-41.00161.00-194.00-23.00-69.0039.0045.00113.0074.5746.73138.19
From investing719-63042469274569587-15333-318-736.89
From financingdividends, buybacks, loans-38-39-332-268-30-41-37-36-30-121-64-64794.44
Net change in cash622-61251-3850-9-1190-1392670195.74
Spent on assetsfiled at the half-year only————————————1,313.24
Free cash flow-64.0054.00-44.00160.00-208.00-24.00-69.0038.0045.00113.0075.3246.68-1,175.05
Cash ÷ operating profitbefore tax—168.00%-164.00%—-1617.00%-192.00%-256.00%144.00%69.00%174.00%82.00%50.00%—

Free cash flow = cash from the business − spending on assets + what assets sold fetched; the same rule for years and half-years.

Efficiency ratios

How fast customers pay and how well capital earns. Each year, Mar 2015 to Mar 2026.

Standalone

Debtor days

38 days

Days customers take to pay. Lower is faster.

38 days in FY26, against 41 days in FY25. Over these 12 years: 23 days (FY17) to 45 days (FY24).

Inventory days

98 days

Days stock sits before it is sold.

98 days in FY26, against 74 days in FY25. Over these 12 years: 74 days (FY25) to 119 days (FY21).

Days payable

101 days

Days it takes to pay its suppliers.

101 days in FY26, against 93 days in FY25. Over these 12 years: 87 days (FY17) to 168 days (FY19).

Cash conversion cycle

35 days

Debtor days plus inventory days, less days payable.

35 days in FY26, against 22 days in FY25. Over these 12 years: −45 days (FY18) to 40 days (FY15).

Working capital days

643 days

Days of sales tied up in running the business.

643 days in FY26, against −45 days in FY25. Over these 12 years: −99 days (FY18) to 643 days (FY26).

Return on capital (ROCE)

16%

Operating profit on the capital used.

16% in FY26, against 17% in FY25. Over these 12 years: 5% (FY20) to 22% (FY16).

At the half-year to Sep 2026: debtor days 25.50, inventory days 291.60, days payable 343.90.

5 · Owners & payouts

Shareholding pattern

Who owns the company: promoters, foreign funds, Indian funds and the public, at each quarter end. In %.

To 30 Sep 2026

Share of the company held by each group, at each filed quarter end, Dec 2023 to Sep 2026.

Promoters

The group that controls the company

70.68%

Since Dec 2023 no change

Foreign funds (FIIs)

Investors outside India

1.21%

Since Dec 2023 +1.02 pts

Indian funds (DIIs)

Mutual funds, insurers, banks

1.50%

Since Dec 2023 +0.98 pts

Public

Individuals and others

26.61%

Since Dec 2023 −1.99 pts

Number of shareholders

Accounts holding the share

38,127

Since Dec 2023 −5,001

  • Foreign funds raised their share from 0.19% to 1.21%; Indian funds raised theirs from 0.52% to 1.50%.
  • Promoters held 70.68% in every quarter from Dec 2023 to Sep 2026.
  • Shareholders fell from 43,128 to 38,127.
Shareholding, % of the company at each quarter end
Holder, %Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoters70.6870.6870.6870.6870.6870.6870.6870.6870.6870.6870.6870.680.00
Foreign funds (FIIs)0.190.190.190.190.190.190.190.190.190.170.161.21+1.02
Indian funds (DIIs)0.520.520.520.520.530.530.530.530.630.531.351.50+0.98
Public28.6028.6128.6028.6128.6028.6128.6028.6128.5028.6027.8126.61−1.99
Shareholders43,12841,23939,26539,59638,92639,13339,04039,35339,46838,11636,50238,127−5,001

A figure in bold moved by 0.5 points or more from the quarter before. Change = Sep 2026 against Dec 2023, in points.

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividend a share, by the year of its ex-date

No dividend in the last three years; the last went ex on 20 Jul 2023, ₹10 a share.

Share of profit paid as dividend

Each year, Mar 2015 to Mar 2026.

Above 100%: it paid out more than that year’s profit.

Splits, bonuses & buybacks

  • Rights 5:1211 Nov 2026

Big trades by funds and insiders

  • KARAN BHAGATbulk deal, BSEBought 1,30,000 · at ₹1,670.527 Sep 2026
  • KYRUSH INVESTMENTSbulk deal, BSESold 1,30,000 · at ₹1,670.507 Sep 2026

6 · Price & trading

Open interestPRO

Where option traders are positioned on this stock.

7 · Business

About

What the company is, from our own records: where it sits, where its revenue comes from, and where it works.

Sector
Healthcare
Industry
Pharmaceuticals
Symbol
EVONILE
ISIN
INE234A01025
Part of
  • BSE Healthcare
+2 more

Sector (1)

  • BSE Healthcare

Wider lists and weighting (2)

  • BSE 1000
  • BSE Total Market Index

Industry numbers

The numbers that matter most in this industry, from the company's own filings and earnings calls. Each one says its period.

Main figures

  • Exports share of revenue0.00%

Brand spend

  • Ad spendFY to Mar 20260.47%

Revenue and margin

  • EBIT marginJun 2026 quarter33.65%

Working capital

  • Days sales outstanding12 months to Sep 202624 days
  • Working capital to sales12 months to Sep 2026-2.11%
  • Customer advancesFY to Mar 2026₹1.77 Cr

Costs

  • Employee costSep 2026 quarter25.63%

Profit quality

  • Other income shareJun 2026 quarter20.25%
  • Interest coverSep 2026 quarter-19.92x

Returns

  • RoE12 months to Mar 202611.61%
  • RoA12 months to Mar 20269.66%
  • Sales to net block12 months to Sep 20260.26x

Leverage

  • Net debt to EBITDA12 months to Sep 202610.73x
  • Debt service coverFY to Mar 202643.80x

Growth

  • Revenue growth (YoY)Sep 2026 quarter-37.78%

Capex

  • CapexFY to Mar 2026₹0.32 Cr
  • Capex to revenueFY to Mar 20260.09%

How they have moved

EBIT margin · quarterly

Source: Computed from the filings

Jun 2633.65%Computed from the filings
Mar 2623.08%Computed from the filings
Dec 2525.58%Computed from the filings
Sep 2525.56%Computed from the filings

Employee cost · quarterly

Source: Computed from the filings

Sep 2625.63%Computed from the filings
Jun 264.54%Computed from the filings
Mar 264.78%Computed from the filings

Other income share · quarterly

Source: Computed from the filings

Jun 2620.25%Computed from the filings
Mar 2633.21%Computed from the filings
Dec 2530.00%Computed from the filings
Sep 2527.27%Computed from the filings

Interest cover · quarterly

Source: Computed from the filings

Sep 26-19.92xComputed from the filings
Jun 26720.50xComputed from the filings
Mar 26431.57xComputed from the filings

Revenue growth (YoY) · quarterly

Source: Computed from the filings

Sep 26-37.78%Computed from the filings
Jun 2618.18%Computed from the filings
Mar 268.33%Computed from the filings
Dec 25-7.53%Computed from the filings

Capex (fiscal year) · yearly

Source: Computed from the filings

FY26₹0.32 CrComputed from the filings
FY25-₹0.32 CrComputed from the filings
FY24₹0.00 CrComputed from the filings

Capex to revenue (fiscal year) · yearly

Source: Computed from the filings

FY260.09%Computed from the filings
FY25-0.09%Computed from the filings
FY240.00%Computed from the filings

Debt service cover (fiscal year) · yearly

Source: Annual report

FY2643.80xAnnual report
FY2543.20xAnnual report

Supply chain

Links to other companies, as recorded in our map from filings and announcements. A news event that hits one of them can reach Evonile Pharma Limited through this map.

Buys from · 1

  • Novartis Pharma AGPharmaceutical finished products for purchase and import

Competes with · 7 companies

Shaded: the companies compared in Key numbers & peers. Each name opens that company’s page.

8 · News & documents

News and what it reaches

Filings and news about Evonile Pharma Limited, and bigger events that reach it through its owners, rivals, customers or suppliers. Newest first. Open one to see how the effect spreads.

  1. 11 Sep 202604:38 IST

    Company newsHealthcareMetals & Mining

    Novartis India enters brand acquisition deal; NALCO partners EGA for Odisha smelter expansion

    Novartis India bought brands to grow its portfolio while NALCO tied up with EGA to expand its Odisha smelter, two company-specific positives.

    News report
    How it spreads
    1. Who it hits first

      • Novartis India scales its domestic brand portfolio
      • NALCO's EGA tie-up de-risks smelter expansion tech and capital
      • Pharma and aluminium peers see no spillover
    2. Who may gain

      • Odisha gains smelter capex and jobs
      • Novartis India's field force gains more to sell
    3. Along the supply chain

      Downstream

      Aluminium buyers gain long-term domestic supply.

      Upstream

      Smelter-equipment and construction vendors gain NALCO orders.

    4. Where demand moves

      Business

      NALCO procures construction and equipment for expansion; Novartis integrates acquired brands into distribution.

    5. How it spreads across sectors

      Healthcare

      Novartis brand deal only; no sector read

      Metals & Mining

      NALCO expansion adds structural supply

    6. When it plays out

      Short term

      Watch deal financials and EGA equity structure.

      Medium term

      Smelter output and brand scale compound over 3-5 years.

  2. 31 Jul 202604:12 IST

    Company newsHealthcare

    Novartis India recast as ChrysCapital-led buyout of Swiss parent's stake completes

    News report
    How it spreads
    1. Who it hits first

      • Novartis India (NOVARTIND) is the company affected - ownership passes from Novartis AG to a ChrysCapital-led private-equity consortium, and the company will be rebranded.
    2. Along the supply chain

      Downstream

      No direct downstream link - hospitals and distributors that buy its medicines face no supply change from the ownership transfer.

      Upstream

      No direct upstream link - a change in who owns Novartis India does not alter what raw materials or active ingredients it buys.

    3. Where demand moves

      Business

      No supply-chain demand shift - this is an ownership change at one drugmaker and does not move orders toward or away from pharma peers like Cipla, Lupin or Sun Pharma.

    4. How it spreads across sectors

      Healthcare

      Minimal ripple - a single already-priced MNC-pharma buyout completion does not move the broader pharma sector.

    5. When it plays out

      Immediate

      Little price impact expected - the catalyst played out in Feb-March 2026.

      Short term

      Watch for the rebranding and any change in strategy or capital allocation under the new private-equity owner.

AI-written from public sources · Information, not advice · Not SEBI-registered

Documents

Earnings calls, results presentations and annual reports, straight from the company and the exchanges.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.